173 related articles for article (PubMed ID: 31764838)
1. Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters.
Abe I; Ochi K; Takashi Y; Yamao Y; Ohishi H; Fujii H; Minezaki M; Sugimoto K; Kudo T; Abe M; Ohnishi Y; Mukoubara S; Kobayashi K
Medicine (Baltimore); 2019 Nov; 98(47):e18067. PubMed ID: 31764838
[TBL] [Abstract][Full Text] [Related]
2. Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis.
Lasco A; Morabito N; Basile G; Atteritano M; Gaudio A; Giorgianni GM; Morini E; Faraci B; Bellone F; Catalano A
Calcif Tissue Int; 2016 Feb; 98(2):123-8. PubMed ID: 26498169
[TBL] [Abstract][Full Text] [Related]
3. Effect of denosumab on glucose metabolism in postmenopausal osteoporotic women with prediabetes: a study protocol for a 12-month multicenter, open-label, randomized controlled trial.
Wang Y; Jiang Y; Li J; Lin X; Luo Y; Tan S; Yang H; Gao Z; Cui X; Yin P; Kong D; Gao Y; Cheng Y; Zhang L; Tang P; Lyu H
Trials; 2023 Dec; 24(1):812. PubMed ID: 38111052
[TBL] [Abstract][Full Text] [Related]
4. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
5. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
6. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
7. Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial.
Sköld C; Kultima K; Freyhult E; Larsson A; Gordh T; Hailer NP; Mallmin H
Osteoporos Int; 2022 Sep; 33(9):1-8. PubMed ID: 35608639
[TBL] [Abstract][Full Text] [Related]
8. A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report.
Horikoshi K; Sakai N; Yamamoto N; Ogura H; Sato K; Miyagawa T; Kitajima S; Toyama T; Hara A; Iwata Y; Shimizu M; Furuichi K; Wada T
BMC Nephrol; 2020 Sep; 21(1):416. PubMed ID: 32993539
[TBL] [Abstract][Full Text] [Related]
9. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
Voskaridou E; Ntanasis-Stathopoulos I; Papaefstathiou A; Christoulas D; Dimopoulou M; Repa K; Papatheodorou A; Peppa M; Terpos E
Blood Adv; 2018 Nov; 2(21):2837-2847. PubMed ID: 30381400
[TBL] [Abstract][Full Text] [Related]
10. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
11. Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis.
Huang HK; Chuang AT; Liao TC; Shao SC; Liu PP; Tu YK; Lai EC
JAMA Netw Open; 2024 Feb; 7(2):e2354734. PubMed ID: 38335002
[TBL] [Abstract][Full Text] [Related]
12. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
13. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.
Sutjandra L; Rodriguez RD; Doshi S; Ma M; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
Clin Pharmacokinet; 2011 Dec; 50(12):793-807. PubMed ID: 22087866
[TBL] [Abstract][Full Text] [Related]
15. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
[TBL] [Abstract][Full Text] [Related]
16. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
17. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
[TBL] [Abstract][Full Text] [Related]
18. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
19. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
